Shanghai Kaibao Pharmaceutical CO.,Ltd

Symbol: 300039.SZ

SHZ

5.73

CNY

Market price today

  • 22.4937

    P/E Ratio

  • 0.5848

    PEG Ratio

  • 6.05B

    MRK Cap

  • 0.01%

    DIV Yield

Shanghai Kaibao Pharmaceutical CO.,Ltd (300039-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ). Companys revenue shows the average of 1006.498 M which is 0.146 % gowth. The average gross profit for the whole period is 824.679 M which is 0.142 %. The average gross profit ratio is 0.820 %. The net income growth for the company last year performance is 0.362 % which equals 0.209 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Shanghai Kaibao Pharmaceutical CO.,Ltd, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.269. In the realm of current assets, 300039.SZ clocks in at 1574.429 in the reporting currency. A significant portion of these assets, precisely 830.765, is held in cash and short-term investments. This segment shows a change of -0.405% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 1175.754, if any, in the reporting currency. This indicates a difference of 78.198% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0 in the reporting currency. This figure signifies a year_over_year change of 0.178%. Shareholder value, as depicted by the total shareholder equity, is valued at 3761.753 in the reporting currency. The year over year change in this aspect is 0.235%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 579.024, with an inventory valuation of 160.8, and goodwill valued at 9.04, if any. The total intangible assets, if present, are valued at 44.23.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

balance-sheet.row.cash-and-short-term-investments

2986.89830.81396.21421.7
1295.1
631.3
685.4
743.2
926.1
816.6
814
841.7
797
832.9
1014.1
29.9
11.3
5.7

balance-sheet.row.short-term-investments

422.88136.151.3114.6
485.6
84.3
103.4
41.6
23.7
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

2556.07579624.7568.6
703.6
758.5
739
653.7
712.8
604.5
447.8
420.3
364
264.1
152.1
138.3
106
63.5

balance-sheet.row.inventory

635.79160.8165.1191.5
190
173.4
181.8
173.3
178.9
108.3
100.7
47.6
41.2
59.1
32.2
32.4
23.7
8.2

balance-sheet.row.other-current-assets

30.393.868.338
74.9
596.5
495.4
352.8
100
190
50
-3.1
-3.1
-3.3
-3.7
-11
-13.2
-0.9

balance-sheet.row.total-current-assets

6209.151574.42254.42219.9
2263.7
2159.6
2101.5
1922.9
1917.8
1719.5
1412.5
1306.5
1199.1
1152.8
1194.7
189.7
127.8
76.6

balance-sheet.row.property-plant-equipment-net

1202.47304.7307.8295.9
326.8
353.3
374.4
372.8
401.1
347.2
313.4
226.7
224.7
187.8
120.7
34.4
31.3
30.5

balance-sheet.row.goodwill

36.16913.818.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

176.7144.242.945.3
41.3
42.1
43.7
45.4
46.8
47.1
42.3
25.9
26.5
27.1
27.8
3.3
1
1.3

balance-sheet.row.goodwill-and-intangible-assets

212.8853.356.763.8
41.3
42.1
43.7
45.4
46.8
47.1
42.3
25.9
26.5
27.1
27.8
3.3
1
1.3

balance-sheet.row.long-term-investments

5123.731175.8659.8165.6
-286.8
98.2
51
139.2
32.1
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

70.7318.315.117.6
11.7
9.5
5
4.9
3.9
3.5
2.6
2
1.9
1.5
1
1.1
0.9
0.6

balance-sheet.row.other-non-current-assets

5130.481132.962114.6
485.8
84.8
104.1
42.6
25
0
0.1
0.1
0.1
1.2
1.3
1.4
0.7
0

balance-sheet.row.total-non-current-assets

11740.292684.81101.4657.4
578.8
587.8
578.2
605
508.8
397.9
358.3
254.6
253.3
217.6
150.7
40.2
33.8
32.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

17949.444259.33355.82877.3
2842.5
2747.4
2679.7
2527.9
2426.7
2117.4
1770.8
1561.1
1452.4
1370.4
1345.4
229.9
161.6
109

balance-sheet.row.account-payables

547.15917562.2
77.9
64.2
60.9
60.7
87.3
38.6
18.7
18.5
15
32.2
8.2
6.8
2.9
17.3

balance-sheet.row.short-term-debt

-20.129.17.735.7
-4.2
0
0
0
0
0
0
0
0
0
118.5
19.3
0
6.5

balance-sheet.row.tax-payables

150.0363.616.420.1
34.8
33.5
27.6
16.1
33.6
44
23
21
18.4
17.7
9.7
6.7
9.2
4.9

balance-sheet.row.long-term-debt-total

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

160.6139.547.251.5
23.6
27.1
34.5
41
45.4
21.7
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

696.19---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

867.46155.8105.10.2
162.1
170.9
218.6
225.8
288.5
172.4
123.5
100.2
88.4
86.4
0.8
0
81.8
0.3

balance-sheet.row.total-non-current-liabilities

856.8202.3120.261.4
33
27.1
34.8
41
45.4
21.7
22.5
23.5
14.6
14.8
13
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

2360.76498.2310.9299
273
262.3
314.3
327.6
421.2
232.7
164.7
142.3
118
133.4
199.2
103
84.6
71.8

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

4184104610461046
1046
1071.5
1071.5
829.4
833.7
640.4
526.1
263
263
175.4
109.6
82.2
12
12

balance-sheet.row.retained-earnings

6557.091567.813851286.9
1294.9
1166.4
1069.5
961.6
789.9
617.5
439.9
284.5
224.3
143.4
65
27.9
55.1
21.7

balance-sheet.row.accumulated-other-comprehensive-income-loss

4848.371148613.9245.5
228.5
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

0000
0
247.2
224.5
409.3
382
626.8
640.1
871.3
847.1
918.3
971.6
16.8
8
3.5

balance-sheet.row.total-stockholders-equity

15589.463761.83044.92578.3
2569.5
2485.1
2365.5
2200.3
2005.5
1884.6
1606.1
1418.8
1334.4
1237
1146.2
126.9
75.1
37.2

balance-sheet.row.total-liabilities-and-stockholders-equity

17949.444259.33355.82877.3
2842.5
2747.4
2679.7
2527.9
2426.7
2117.4
1770.8
1561.1
1452.4
1370.4
1345.4
229.9
161.6
109

balance-sheet.row.minority-interest

-0.78-0.700
0
0
0
0
0
0
0
0
0
0
0
0
1.9
0

balance-sheet.row.total-equity

15588.6837613044.92578.3
2569.5
2485.1
2365.5
2200.3
2005.5
1884.6
1606.1
1418.8
1334.4
1237
1146.2
126.9
77
37.2

balance-sheet.row.total-liabilities-and-total-equity

17949.44---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

5546.611311.8711.1280.2
198.8
182.4
154.3
180.8
55.8
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

23.379.17.735.7
0
0
0
0
0
0
0
0
0
0
118.5
19.3
0
6.5

balance-sheet.row.net-debt

-2540.65-685.6-1337.2-1271.4
-809.5
-547.1
-582
-701.6
-902.4
-816.6
-814
-841.7
-797
-832.9
-895.6
-10.6
-11.3
0.8

Cash Flow Statement

The financial landscape of Shanghai Kaibao Pharmaceutical CO.,Ltd has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 3.128. The company recently extended its share capital by issuing 0, marking a difference of 0.000 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 76.9 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -285373358.970 in the reporting currency. This is a shift of 2.417 from the previous year. In the same period, the company recorded 31.71, -303, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -52.3 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

cash-flows.row.net-income

268.32190.1140.1106.1
251
226.8
272.3
282.6
281.6
349.4
318.8
242.2
167.6
123.7
68.7
57.7
44.8
20.9

cash-flows.row.depreciation-and-amortization

26.3131.733.940.8
48.1
47.8
48.8
51
51
38.1
29.5
27.5
21.8
12.9
5.6
4.8
4.1
3.4

cash-flows.row.deferred-income-tax

0-3.32.6-6.6
-3
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

03.3-2.66.6
3
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0136-49.5103.8
32.9
-54.9
-69.5
-30.1
-9.8
-111.3
-82.3
-26.5
-92.1
-120.7
-23.8
-47.4
-28.7
-6.3

cash-flows.row.account-receivables

058.3-74.9137.9
57.5
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

04.127.2-2.2
-17.5
8.6
-7.2
4.2
-52
-7.6
-53.1
-6.4
17.9
-26.8
0.2
-8.7
-15.5
-4.5

cash-flows.row.account-payables

076.9-4.4-25.2
-4.1
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-3.32.6-6.6
-3
-63.4
-62.3
-34.3
42.1
-103.6
-29.2
-20.1
-110
-93.9
-24
-38.6
-13.2
-1.8

cash-flows.row.other-non-cash-items

140.5118.61.6-0.1
2.1
42.6
-5.8
11.3
4.3
6.2
4.2
0.2
1.1
3.9
2.3
3.6
3.1
1.7

cash-flows.row.net-cash-provided-by-operating-activities

435.14000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-45.34-31.6-42.5-13.9
-15.5
-26.1
-49.2
-27
-50.4
-68.7
-118.3
-52.2
-68.9
-51
-125.7
-11.3
-4.6
-11.7

cash-flows.row.acquisitions-net

-0.640.3-14.5-4.5
0.1
0
0
0
0.1
0
0
0
3.3
0
125.7
11.3
0
0

cash-flows.row.purchases-of-investments

-913.22-1657.8-2352.6-1786.7
-1172.3
-260.3
-867.6
-1250.1
-239.5
0
0
0
0
0
-6.4
-3.4
0
0

cash-flows.row.sales-maturities-of-investments

1003.741706.82390.72121.4
1339.9
322
782.9
1013.8
94.6
0
0
0
0
0
6.4
1.5
0
0

cash-flows.row.other-investing-activites

-136.54-303-64.5-251.1
-753
-209.7
-88
-172
90
-140
-50
0.1
0.1
0
-251.4
-11.3
0
0

cash-flows.row.net-cash-used-for-investing-activites

-92-285.4-83.565.2
-600.8
-174
-221.9
-435.3
-105.3
-208.7
-168.3
-52.1
-65.5
-51
-125.7
-13.2
-4.6
-11.7

cash-flows.row.debt-repayment

00-37.7-35.7
0
-16
0
0
-30
-35
0
0
0
-118.5
-35.6
-11.2
-13
-9.7

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
-117.4
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-62.76-52.3-31.6-105.1
-106.4
-107.1
-107.1
-82.4
-130.3
-136.8
-131.5
-157.8
-70.1
-33.2
-30.3
-21.2
-7.8
-4.8

cash-flows.row.other-financing-activites

-62.760-0.371.4
0
-0.1
-10.9
-23.8
21.1
100.8
1.9
11.4
1.4
1.8
1123.1
45.5
7.7
8.5

cash-flows.row.net-cash-used-provided-by-financing-activities

-62.76-52.3-69.4-69.4
-223.8
-123.3
-118.1
-106.2
-139.2
-71
-129.6
-146.5
-68.8
-149.9
1057.1
13.1
-13.1
-6

cash-flows.row.effect-of-forex-changes-on-cash

-1.06000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

275.338.7-26.8246.5
-490.5
-35
-94.2
-226.7
82.6
2.6
-27.7
44.7
-35.9
-181.1
984.1
18.6
5.6
2

cash-flows.row.cash-at-end-of-period

1977.98314.5275.7302.5
56.1
546.6
581.5
675.7
902.4
816.6
814
841.7
797
832.9
1014.1
29.9
11.3
5.7

cash-flows.row.cash-at-beginning-of-period

1702.69275.7302.556.1
546.6
581.5
675.7
902.4
819.8
814
841.7
797
832.9
1014.1
29.9
11.3
5.7
3.8

cash-flows.row.operating-cash-flow

435.14376.4126.1250.6
334.1
262.4
245.8
314.9
327.1
282.4
270.2
243.3
98.3
19.8
52.7
18.7
23.3
19.7

cash-flows.row.capital-expenditure

-45.34-31.6-42.5-13.9
-15.5
-26.1
-49.2
-27
-50.4
-68.7
-118.3
-52.2
-68.9
-51
-125.7
-11.3
-4.6
-11.7

cash-flows.row.free-cash-flow

389.8344.883.5236.7
318.6
236.3
196.5
287.8
276.7
213.6
152
191.1
29.5
-31.2
-73
7.4
18.7
8

Income Statement Row

Shanghai Kaibao Pharmaceutical CO.,Ltd's revenue saw a change of 0.017% compared with the previous period. The gross profit of 300039.SZ is reported to be 871.28. The company's operating expenses are 666.85, showing a change of -8.958% from the last year. The expenses for depreciation and amortization are 31.71, which is a -0.063% change from the last accounting period. Operating expenses are reported to be 666.85, which shows a -8.958% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.329% year-over-year growth. The operating income is 228.37, which shows a 0.329% change when compared to the previous year. The change in the net income is 0.362%. The net income for the last year was 190.8.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006

income-statement-row.row.total-revenue

1473.171118.91100.6908
1419
1500.7
1569.9
1497.2
1395.8
1481.1
1323.2
1102
820
603.4
458.9
387.4
258.1
166.5

income-statement-row.row.cost-of-revenue

316.17247.6234.9179.9
251.2
263.7
291.8
280.7
250.4
230
204.4
178.7
149
107.5
78.3
69.6
45.7
27.6

income-statement-row.row.gross-profit

1157871.3865.7728.2
1167.8
1237
1278.1
1216.4
1145.4
1251.1
1118.9
923.3
671
495.9
380.6
317.8
212.3
138.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

93.6---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

34.81---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

691.7---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

2.311.98.7-1.8
-0.6
-0.2
-5.2
8.2
6.9
-19
-1.9
-3.5
15.7
2.4
14.5
8.6
10.3
4.4

income-statement-row.row.operating-expenses

869.36666.9732.5633.4
884.4
931.4
964.6
900.9
843.5
858.9
785.6
679.6
507.5
378.7
312.6
254.8
169.6
119.3

income-statement-row.row.cost-and-expenses

1185.52914.4967.4813.2
1135.6
1195
1256.4
1181.7
1093.9
1088.9
990
858.3
656.5
486.3
390.9
324.4
215.3
146.9

income-statement-row.row.interest-income

41.9342.740.339.6
20.4
11.8
13.2
20.8
30.3
24.1
25.1
23.2
20.2
16
0.1
0.2
0
0

income-statement-row.row.interest-expense

00.10.10.5
0
0.1
0.1
0
2.2
20.8
0
0
0
0.4
3.1
1.9
0.8
0.7

income-statement-row.row.selling-and-marketing-expenses

691.7---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-1.79-2.2-2.2-2.8
-0.6
-0.2
-5.2
8.1
6.9
4.9
23.1
19.6
15.7
18.1
14.5
8.6
10.3
4.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

2.311.98.7-1.8
-0.6
-0.2
-5.2
8.2
6.9
-19
-1.9
-3.5
15.7
2.4
14.5
8.6
10.3
4.4

income-statement-row.row.total-operating-expenses

-1.79-2.2-2.2-2.8
-0.6
-0.2
-5.2
8.1
6.9
4.9
23.1
19.6
15.7
18.1
14.5
8.6
10.3
4.4

income-statement-row.row.interest-expense

00.10.10.5
0
0.1
0.1
0
2.2
20.8
0
0
0
0.4
3.1
1.9
0.8
0.7

income-statement-row.row.depreciation-and-amortization

-6.6831.733.940.8
48.1
47.8
48.8
51
51
38.1
29.5
27.5
21.8
12.9
5.6
4.8
4.1
3.4

income-statement-row.row.ebitda-caps

316.23---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

322.91228.4171.8134.4
301.8
274.9
332.6
325.1
327.9
409.9
354
266.6
182.5
129.2
65.7
59.8
39.8
17.9

income-statement-row.row.income-before-tax

321.11226.2169.7131.6
301.2
274.7
327.4
333.2
334.8
414.8
377.1
286.2
198.2
147.3
80.2
68.4
50.1
22.3

income-statement-row.row.income-tax-expense

53.2436.129.525.5
50.2
47.9
55.1
50.6
53.2
65.5
58.3
44
30.7
23.6
11.6
10.8
5.3
1.4

income-statement-row.row.net-income

268.32190.8140.1106.1
251
226.8
272.3
282.6
281.6
349.4
318.8
242.2
167.6
123.7
68.7
57.7
44.8
20.9

Frequently Asked Question

What is Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ) total assets?

Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ) total assets is 4259271286.000.

What is enterprise annual revenue?

The annual revenue is 694941010.000.

What is firm profit margin?

Firm profit margin is 0.785.

What is company free cash flow?

The free cash flow is 0.373.

What is enterprise net profit margin?

The net profit margin is 0.182.

What is firm total revenue?

The total revenue is 0.219.

What is Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ) net profit (net income)?

The net profit (net income) is 190804507.000.

What is firm total debt?

The total debt is 9101607.000.

What is operating expences number?

The operating expences are 666850096.000.

What is company cash figure?

Enretprise cash is 571456310.000.